KZIA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 mai 2024 @ 22:00):

Stats
Dagens volum	44 505.00
Gjennomsnittsvolum	467 487
Markedsverdi	6.66M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00600 (2.13%)

Insider Trading

Date	Person	Action	Amount	type
2013-11-04	Austin Josiah T	Sell	25 400	Sponsored ADRs, each convertible into 25 ordinary shares
2013-11-05	Austin Josiah T	Sell	23 922	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-25	Austin Josiah T	Sell	62 591	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-28	Austin Josiah T	Sell	37 409	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-29	Austin Josiah T	Sell	1 100	Sponsored ADRs, each convertible into 25 ordinary shares

INSIDER POWER
0.00
Last 100 transactions
Buy: 5 568 614 \| Sell: 243 947

Volum Korrelasjon

Lang: -0.55 (weak negative)

Kort: -0.84 (strong negative)

Signal:(54.233) Neutral

Kazia Therapeutics Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kazia Therapeutics Korrelasjon - Valuta/Råvare

-0.15
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.12
( neutral )

Kazia Therapeutics Økonomi

Annual	2023
Omsetning:	$555.00
Bruttogevinst:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2023
Omsetning:	$555.00
Bruttogevinst:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2022
Omsetning:	$25.00
Bruttogevinst:	$25.00 (100.00 %)
EPS:	$-1.860

FY	2021
Omsetning:	$15.18M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.716

Financial Reports:

No articles found.

Kazia Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.